OR WAIT null SECS
Alvotech and Prestige Biopharma, have announced the formation of a new contract manufacturing partnership for the commercial production of a biosimilar.
Biopharmaceutical companies, Alvotech and Prestige Biopharma, have announced in an Aug. 27, 2019 press release the formation of a new contract manufacturing partnership for the commercial production of a biosimilar.
As per the agreement, Alvotech Contract Services will assume the responsibilities of commercially producing one of Prestige Biopharma’s biosimilar candidates. Production of the biosimilar will take place at Alvotech’s new biosimilar facility based in Reykjavik, Iceland. Scale up and process validation of the manufacturing process will be performed at the Reykjavik facility also.
“The partnership with Prestige BioPharma marks an important milestone for our company as we work towards expanding our contract manufacturing business,” said Mark Levick, Alvotech’s CEO, in the press release. “We are pleased to be trusted with the responsibility of delivering high quality manufacturing services to Prestige Biopharma and look forward to further collaboration in the future. We pride ourselves on delivering highest quality commercial production from one of the best biopharma facilities in the world.”
Both companies will start technology transfer immediately, which will be followed by commercial manufacture of the compound.